BACKGROUND
Transcatheter aortic valve implantation (TAVI) is an established therapy for severe aortic stenosis. Among patients with left ventricular (LV) systolic dysfunction, recovery of LV function after TAVI is heterogeneous, and reliable tools for pre-procedural risk stratification and patient counseling remain lim...
Yuki Hida, Teruhiko Imamura, H. Ueno et al.· Catheterization and cardiova...· 0 citations
BACKGROUND
Bioprosthetic valve failure (BVF) is a key clinical endpoint for evaluating valve durability after transcatheter aortic valve implantation (TAVI). However, in populations with substantial competing mortality or heterogeneous follow-up durations, the estimated incidence of BVF may vary according to evaluation...
H. Hioki, M. Yamamoto, T. Shimura et al.· International Journal of Car...· 0 citations
Background Patients with extremely small aortic annuli are at increased risk of residual gradients and prosthesis-patient mismatch (PPM) after transcatheter aortic valve replacement (TAVR). Comparative data on contemporary valve platforms in this subset remain limited. Objectives The authors aimed to compare early clin...
Shinichi Shirai, H. Hioki, M. Yamamoto et al.· JACC: Asia· 1 citation
We aimed to investigate association of three DanGer Shock trial criteria [systolic blood pressure [SBP] < 100 mmHg, lactate ≥ 2.5 mmol/L, and left ventricular ejection fraction (LVEF) < 45%] on clinical outcomes among patients with ST-elevation myocardial infarction (STEMI) in Japan and evaluate whether these criteria...
Narumi Irie, Y. Sawayama, Mikitaka Fujita et al.· Heart and Vessels· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.